Form 4: Boston Scientific CEO Michael Mahoney Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock on April 1, 2025, under a pre-established Rule 10b5-1 trading plan.
Summary
- On April 1, 2025, Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corp (BSX), executed stock options to acquire 56,211 shares at $17.26 and 49,407 shares at $24.55.
- He then sold 164,442 shares at a weighted average price of $100.0053, with individual sales ranging from $99.50 to $100.40.
- These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024.
- Following these transactions, Mahoney directly owns 1,594,530 shares and indirectly owns 201,478 shares through a trust.
Sentiment
Score: 5
Explanation: The document itself is neutral, simply reporting transactions. The use of a 10b5-1 plan suggests pre-planned activity, reducing potential negative sentiment. However, any insider selling can create slight uncertainty.
Positives
- The transactions were executed under a pre-established Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Risks
- Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.
Industry Context
Executive stock transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information. Investors often monitor these transactions for insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Executive compensation practices, including stock options and sales, are generally benchmarked against peer companies in the medical device industry, such as Medtronic, Abbott, and Stryker.
- The use of Rule 10b5-1 trading plans is a common practice among executives in these companies to manage their personal finances and diversify their holdings.
Stakeholder Impact
- Shareholders may monitor these transactions for insights into management's perspective on the company's value.
- The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2017-02-22 | First vesting date of stock options granted to Mahoney. |
| 2018-02-28 | First vesting date of stock options granted to Mahoney. |
| 2024-11-15 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2025-04-01 | Date of stock option exercise and share sale. |
| 2026-02-22 | Expiration date of stock options granted to Mahoney. |
| 2027-02-28 | Expiration date of stock options granted to Mahoney. |
Keywords
Boston Scientific, BSX, Michael Mahoney, Stock Options, Share Sale, Rule 10b5-1, Insider Trading, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.